Blackstone Life Sciences agreed to provide Apogee Therapeutics with up to $1.3 billion in non-dilutive financing to advance zumilokibart (zumi) into Phase III for moderate-to-severe atopic dermatitis. The structure combines royalty financing and senior corporate debt, with milestone-based drawdowns tied to Phase III enrollment progress and FDA approval. Apogee accompanied the deal with 16-week Part B induction data from its Phase II APEX trial, reporting that 65.9% of patients achieved at least a 75% reduction in eczema severity. The company framed the antibody as a potentially differentiated long-acting anti-IL-13 option, with dosing and efficacy positioning it for broader immunology opportunities. For the market, the transaction is notable as a large royalty-backed package before Phase III, reducing dilution pressure as Apogee scales late-stage operations. It also signals investor appetite for specialty immunology assets with clear efficacy signals and defined regulatory milestones. Apogee’s next catalysts are Phase III initiation timing and regulators’ expectations around durability, safety, and endpoint strategy.